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Invited Editorial
Testing for recombinant human erythropoietin
Joris R. Delanghe1 and Michael J. Joyner2
1Department of Clinical Chemistry, Ghent University Hospital, Ghent, Belgium; 2Department of Anesthesiology, Mayo Clinic,
Rochester, Minnesota
ERYTHROPOIETIN (Epo) may have effects on exercise capacity
and physiological regulation beyond a simple increase in red
cell mass and the associated improvement in oxygen transport
(4). In the context of a larger study on this topic, Lundby and
colleagues (11) also asked questions about the reliability of
urine testing for recombinant human Epo (rHuEpo). They
studied eight healthy male subjects during a 4-wk “loading”
and 2-wk “boosting” phase of Epo use followed by a 2-wk
maintenance phase. In the parent study they showed that the
effects of Epo on exercise performance were confined to its
impact on red cell mass and not to other physiological effects
of the hormone. These results were consistent with ideas about
the relationship between maximal oxygen uptake and red cell
mass or total body hemoglobin that emerged in the 1950s. The
findings are timely and have implications for public policy relat-
ing to the control of doping practices. In this short report a number
of challenges related to urine testing for Epo are highlighted.
Testing for recombinant Epo in urine may seem practical at
first sight but appears to be a very difficult task. The amount of
endogenous Epo in urine is extremely low (5). The physiolog-
ical background for testing Epo in urine is complex and the
handling of Epo by the renal tubules is poorly understood (16).
Furthermore, exercise-induced renal ischemia and the accom-
panying postexercise proteinuria may affect the clearance of
this 32- to 39-kDa protein and the quality of the urine matrix.
The Epo test that has been adopted in World Anti-Doping
Agency (WADA)-accredited laboratories is based on isoelec-
tric focusing (2, 10). Since the introduction of the test in 2000,
Epo-abusing athletes have altered their dosing schemes, prov-
ing the initial efficiency of the test. By injecting microdoses of
rHuEpo, the window of detection can be reduced to as little as
12–18 h postinjection (8).
Several problems (e.g., the lengthy sample preparation,
the low sample load capacity, difficulties with interlabora-
tory standardization, non-specific binding of the secondary
antibody to urinary proteins, sensitivity issues) were already
identified in a WADA-commissioned report in 2003 (14).
The test requires a 700- to 1,000-fold concentration of the
specimen before analysis can be carried out, and the con-
centrated urine forms a pellet that is difficult to solubilize.
Despite this enormous concentration factor, up to 20% of
the investigated samples do not show detectable Epo (14).
The non-specific interaction of the used monoclonal anti-
body with human, bacterial, and yeast proteins is worrisome
(4, 6). Epo test results are clearly not always interpreted
identically (4). The use of the software processing has been
criticized (6).
The American WADA-accredited laboratory has performed
the direct Epo test on more than 2,600 samples, only nine of
them were found to be positive (3). The low numbers of
athletes caught by the test are somewhat contradictory to the
overall increase of mean hematocrit values since rHuEpo
became available (12). Additionally, in some high profile legal
cases in the United States, athletes who were clearly doping
with a variety of compounds including Epo “passed” hundreds
of individual drug tests.
Along these lines, Lundby et al. (11) convincingly demon-
strated that the performance of the urinary Epo test is some-
what disappointing. Although the judgment process of “real”
doping cases differs from the one applied in the present study,
the high number of false-negative results imply a risk that
athletes doping with Epo will avoid detection and damage the
fundamental goal of fair competition. The earlier reported
flaws of the test help to understand the relatively low efficiency
of the direct Epo test and the current results emphasize the need
for improving Epo testing.
The detection window for Epo shows an interindividual
variation because the actual positivity criteria take into consid-
eration the endogenous Epo production rate, which varies
enormously between individuals. In subjects with a naturally
elevated or stimulated Epo production rate (altitude training,
hypoxic tent, etc.), there is a reduced detection window. The
positivity criteria used by anti-doping laboratories are strict and
(in the case of the Epo analog darbepoietin) could be adapted
by only taking into account the position and the specific
distribution of the bands in the most acidic area of the gel and
no longer the intensity of the bands. This would rule out the
differences in interpretation of the test due to different endog-
enous Epo levels in individual athletes (8). While the perfor-
mance of the existing test can likely be improved by paying
more attention to the preanalytical care after prelevation of
urine specimens (4), there also is concern about protease-
treated urine specimens that could mask Epo abuse (9).
On the other hand, blood-based indirect Epo tests have a
better physiological basis and offer the advantage that other
kinds of blood doping can also be detected (1, 13, 15). This
approach focuses on consistent tracking and establishes upper
limits of normal permitted for competition. The so-called
“passport” approach will be further facilitated by the increased
availability of well-validated mobile hematological analysis
equipment. Longitudinal monitoring of blood profiles and
comparing an athlete’s individual hematological values against
his or her own historical baseline rather than a population-
derived threshold further enhances the potency of indirect
testing (1). In the Union Cycliste International (UCI), the
governing body of cycling, anti-doping program “100% Against
Doping,” an individual hematological profile is created. How-
ever, indirect Epo/blood doping detection methods require
blood sampling, which is a practical disadvantage. Addition-
ally, various dietary or saline infusion strategies for the pur-
poses of short-term hemodilution are likely being practiced to
circumvent the “passport” approach prior to important compe-
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titions (7). Does this mean that a combination of regular
tracking tests with random elements along with a marker of
whole body fluid status is needed?
In summary, the data provided by Lundby et al. demonstrate
that an improvement in the current Epo test is necessary or that
a different strategy to detect Epo use and blood doping should
be considered. Blood-based indirect Epo tests offer an inter-
esting alternative. The rapidly changing blood doping land-
scape will definitely encourage the use of indirect Epo/blood
doping testing with a much broader application.
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